Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RAP-1332
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
RAP-1332 is a preclinical-stage homodimeric recombinant fusion protein (ligand trap) developed by Acceleron Pharma (now Merck & Co.) that selectively binds and neutralizes transforming growth factor beta 1 (TGF-β1) and transforming growth factor beta 3 (TGF-β3). It serves as a murine surrogate/orthologue of the human therapeutic candidate ACE-1332. Structurally, RAP-1332 consists of the extracellular domain of murine TGF-beta receptor type II (TGFβRII) fused to a murine IgG2a Fc domain. By sequestering TGF-β1 and TGF-β3, RAP-1332 prevents ligand-receptor engagement and downstream SMAD2/3 signaling, thereby blocking epithelial-to-mesenchymal transition (EMT) and fibroblast-to-myofibroblast transition (FMT). It has been evaluated in preclinical mouse models of chronic biliary injury, primary sclerosing cholangitis (PSC)-like biliary injury, liver fibrosis, myelofibrosis, and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
- Other names
- murine TGF-beta trap RAP-1332murine TGFβRII-Fc
02
Targets
TGFB1 (Transforming growth factor Beta-1 proprotein)TGFB3 (Transforming growth factor beta 3)
Beyond the preview
Go deeper on RAP-1332.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAP-1332.